Director/PDMR Notification

RNS Number : 6732D

Advanced Oncotherapy PLC

04 March 2022

 

4 March 2022

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Director/PDMR Notification

Advanced Oncotherapy (AIM: AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, announces that Prof. Steve Myers, Executive Director and Executive Chairman of ADAM SA , yesterday purchased 25,000 ordinary shares of 25 pence each in the Company ("Ordinary Shares"), at a price of 26 pence per share and 115,000 Ordinary Shares at a price of 28 pence per share. Following these purchases, Prof. Myers now has a total interest in 1,540,569 Ordinary Shares, equivalent to 0.34% of the Company's issued share capital.

The notification below, which has been made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

Advanced Oncotherapy plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Allenby Capital Limited  (Nomad and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking)	Tel: [phone]
SI Capital Ltd  (Joint Broker)
Nick Emerson	Tel: [phone]
Jon Levinson	Tel: [phone]
FTI Consulting  (Financial PR & IR)	[e-mail]
Simon Conway / Rob Winder	Tel: [phone]

About Advanced Oncotherapy Plc

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 

1	Details of the person discharging managerial responsibilities
a)	Name	Prof. Stephen Myers
2	Reason for the notification
a)	Position/status	Executive Director & Executive Chairman of ADAM SA
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Advanced Oncotherapy plc
b)	LEI	213800LUDHZOG3YT6C82
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 25p each in  Advanced Oncotherapy plc Identification code (ISIN) for  Advanced Oncotherapy plc ordinary shares: GB00BD6SX109
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	Price: 26.0p Volume: 25,000 shares Price: 28.0p Volume: 115,000 shares
d)	Aggregated information - Aggregated volume - Price	n/a
e)	Date of the transaction	2 March 2022
f)	Place of the transaction	London Stock Exchange, (XLON)

 

END

 

 

DSHFZGGFRDRGZZG